This newsletter presents you the following key sessions:
1. PODCAST Nadia Harbeck about the KAITLIN study
2. Maintenance avelumab after platinum-based first-line chemotherapy prolongs the survival of patients with
advanced urothelial carcinoma
3. Biomarker analyses from the phase III CheckMate 214 trial evaluating nivolumab plus ipilimumab in
patients with advanced renal cell carcinoma: the search continues
4. Pronounced clinical benefit of FOLFIRI plus ramucirumab as second-line therapy for docetaxel pre-treated
patients with advanced gastro-oesophageal adenocarcinoma
5. Long-term benefit with encorafenib/binimetinib in patients with BRAFV600-mutated melanoma
Please consult the prescribing information before prescribing via https://www.famhp.be/en